Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Artificial intelligence-driven new drug discovery targeting serine/threonine kinase 33 for cancer treatment

Fig. 2

Distinct anti-cancer efficacy of a new STK33 inhibitor, Z29077885. A Simulation of docking site at STK33 for Z29077885, BRD-8899, and ML-281. B Anti-cancer efficacy on cell viability of Z29077885, BRD-8899, or ML-281 in THP-1, NOMO-1, and SKM-1 cell lines in vitro. C Cell viability after Z356388010 treatment with varying concentrations in THP-1 cells in vitro was measured by Cell-titer Glo. Table 2 Summary of cell viability after 10uM of Z29077885 treatment in vitro. Error bars represent SD over biological replicates. The p values were obtained using One-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us